Interpretation Death from bleeding occurs soon after onset and even a short delay in treatment reduces the benefit of tranexamic acid administration. Patients must be treated immediately. Further research is needed to deepen our understanding of the mechanism of action of tranexamic acid.
Introduction
Acute severe bleeding is a leading cause of death. 1 Traumatic extracranial haemorrhage, often the conse quence of road traffic crashes or violence, is respons ible for more than two million deaths each year. 2 Traumatic and spontaneous intracranial bleeding are common causes of death and disability. 3 Severe surg ical haem orrhage strongly predicts adverse patient outcomes and is associated with an increase in the odds of death by eight times. 4 Thousands of patients are admitted to hospital with gastrointestinal bleeding each year in the UK, with a case fatality of about 10% for upper gastrointestinal bleeding and 3% for lower gastrointestinal bleeding. 5,6 Postpartum haem orrhage accounts for about 100 000 maternal deaths each year worldwide, with the majority occurring in less developed countries. 7 Antifibrinolytic drugs (tranexamic acid, aminocaproic acid, aprotinin, and aminomethylbenzoic acid) reduce bleeding by inhibiting the breakdown of fibrin clots. 8, 9 Antifibrinolytics reduce surgical bleeding and the need for transfusion by about a third, irrespective of the site of surgery. 10 Administration of tranexamic acid within 3 h of bleeding onset reduces deaths from bleeding in patients with trauma and post partum haemorrhage. [11] [12] [13] We sought to quantify the effect of treatment delay on the effectiveness of antifibrinolytics in acute severe bleeding by analysing individual patientlevel data from random ised placebo controlled trials. Methods We did an individual patient-level data meta-analysis of randomised trials done with more than 1000 patients that assessed antifibrinolytics in acute severe bleeding. We identified trials done between Jan 1, 1946, and April 7, 2017, from MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, PubMed, Popline, and the WHO International Clinical Trials Registry Platform. The primary measure of treatment benefit was absence of death from bleeding. We examined the effect of treatment delay on treatment effectiveness using logistic regression models. We investigated the effect of measurement error (misclassification) in sensitivity analyses. This study is registered with PROSPERO, number 42016052155.
Findings
We obtained data for 40 138 patients from two randomised trials of tranexamic acid in acute severe bleeding (traumatic and post-partum haemorrhage). Overall, there were 3558 deaths, of which 1408 (40%) were from bleeding. Most (884 [63%] of 1408) bleeding deaths occurred within 12 h of onset. Deaths from post-partum haemorrhage peaked 2-3 h after childbirth. Tranexamic acid significantly increased overall survival from bleeding (odds ratio [OR] 1·20, 95% CI 1·08-1·33; p=0·001), with no heterogeneity by site of bleeding (interaction p=0·7243). Treatment delay reduced the treatment benefit (p<0·0001). Immediate treatment improved survival by more than 70% (OR 1·72, 95% CI 1·42-2·10; p<0·0001). Thereafter, the survival benefit decreased by 10% for every 15 min of treatment delay until 3 h, after which there was no benefit. There was no increase in vascular occlusive events with tranexamic acid, with no heterogeneity by site of bleeding (p=0·5956). Treatment delay did not modify the effect of tranexamic acid on vascular occlusive events.
